Classification: Other Corporate Update (Subsidiary Funding)
Nature of Update:
The Renewable Energy and Subsidiary Investment Committee (RESIC) of Max Healthcare Institute Limited approved an infusion of funds into its subsidiary, Kalinga Hospital Ltd. (KHL), through a rights issue subscription.
Key Operational or Strategic Points:
- The investment amount is approximately ₹87.87 Crore
- Funding will be used to support KHL's capital expenditure and modernization programme
- Objectives include strengthening KHL's clinical and operational capabilities
- Funds will help optimize KHL's capital structure
- Additional purposes include meeting general corporate requirements of KHL
- Transaction is exempt from related party transaction requirements under SEBI LODR Regulations
- No promoter/promoter group/group companies have any interest in KHL beyond the Company's existing shareholding
Material Financial Impact:
- Cash outflow of ₹87.87 Crore from Max Healthcare Institute Limited
- Investment made through subscription to equity shares on rights basis
- KHL's financial metrics as disclosed:
- Paid-up Capital: ₹21.54 Crore
- Revenue from Operations during FY 2025-26: ~₹155.64 Crore
Timeline:
- The acquisition is expected to be completed within the next 15 days from September 3, 2026
- RESIC meeting was held on September 3, 2026, commencing at 2:50 pm IST and concluding at 3:22 pm IST
Approval Status:
- Approved by the Renewable Energy and Subsidiary Investment Committee (RESIC)
- RESIC is a duly authorized Committee by the Board of Directors of the Company
- No governmental or regulatory approvals required for this acquisition
Reference Regulation:
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regulation 30